Recurrent hydatiform mole: a rare case report
Keywords:
Recurrent, Hydatiform mole, Genetic predispositionAbstract
Molar pregnancy is characterized histologically by abnormalities of the chorionic villi that consist of trophoblastic proliferation and oedema of villous stroma. The incidence of hydatiform moles in India is 1 in 1000. The incidence of recurrence is 1 in 60 in a subsequent pregnancy and 1 in 65 in the third pregnancy after two molar pregnancies. The occurrence of hydatiform mole is related to a few risk factors such as smoking, increased paternal or maternal age, and previous history of abortions. Here we report a case of a 29 year old woman with history of four partial moles and two first trimester abortions and her management. The patient finally opted for adoption.
Metrics
References
Cunningham FG, Leveno KT, Bloom SL, Hauth JC. Williams Obstetrics. 23rd edition. Vol. 2. New York, NY, USA: McGraw-Hill; 2009:257-64.
Palmer JR. Advances in the epidemiology of gestational trophoblastic disease. J Reprod Medicine 1994;39:155-62.
R.S. Berkowitz, Z. S. Tuncer, M. R. Bernstein, and D. P. Goldstein, “Management of gestational trophoblastic diseases: subsequent pregnancy experience,” Seminars in Oncology, vol. 27, no. 6, pp. 678–685, 2000.
A. D. Altman, B. Bentley, S. Murray, and J. R. Bentley, “Maternal age-related rates of gestational trophoblastic disease,” Obstetrics and Gynecology, vol. 112, no. 2, pp. 244–250, 2008.
Levitas E, Lunenfeld E, Weisz N, Friger M, Potashnik G. Relationship between age and semen parameters in men with normal sperm concentration: Analysis of 6022 semen samples. Andrologia 2007;39:45-50.
Palmer JR, Driscoll SG, Rosenberg L, Berkowitz RS, Lurain JR, Soper J, et al. Oral contraceptive use and risk of gestational trophoblastic tumours. J Natl Cancer Inst 1999;91:635-40
Pour Reza M, Agheli N, Baghefi SB. Serum creatinine and urea and protein level changes in hydatidiform mole. JAMA 1974;230:580-1.
Moglabey YB, Kircheisen R, Seoud M, El Mogharbel N, Van den Veyver I, Slim R. Genetic mapping of a maternal locus responsible for familial hydatidiform moles. Hum Mol Genet 1999;8:667-71.
Altieri A, Franceschi S, Ferlay J, Smith J, La Vecchia C. Epidemiology and aetiology of gestational trophoblastic diseases. Lancet Oncol 2003;4:670-8.
Sebire NJ, Fisher RA, Foskett M, Rees H, Seckl MJ, Newlands ES. Risk of recurrent hydatiform mole and subsequent pregnancy outcome following complete or partial hydatiform molar pregnancy. BJOG 2003; 110:22-6.
S. D. Lawler, R. A. Fisher, and J. Dent, “A prospective genetic study of complete and partial hydatidiform moles,” American Journal of Obstetrics and Gynecology, vol. 164, no. 5, pp. 1270-1277, 1991.
E. Garner, “Malignant gestational trophoblastic disease: staging and treatment,” in UpToDate [Textbook of Medicine], B. Goff, S. Falk, and D. M. F. Savarese, Eds., UpToDate, Waltham, Mass, USA, 2011.
S. D. Lawler, R. A. Fisher, and V. J. Pickthall, “Genetic studies on hydatidiform moles. I. The origin of partial moles,” Cancer Genetics and Cytogenetics, vol. 5, no. 4, pp. 309-320, 1982.
P. K. Sand, J. R. Lurain, and J. I. Brewer, “Repeat gestational trophoblastic disease, ”Obstetrics and Gynecology 1984;63:140-4.
Reubinof BE, Lewin A, Verner M, Safran A, et al. Intracytoplasmic sperm injection combined with preimplantation genetic diagnosis for prevention of recurrent gestational trophoblastic disease. Hum Reprod 1997;12(4):805-09.
Seckl MJ, Rustin GJ. Late toxicity after therapy for gestational trophoblastic tumours. In: Hancock BW, Newlands ES, Berkowitz RS, Cole LA, editors. Gestational Trophoblastic Disease. 3rd ed. London: International Society for the Study of Trophoblastic Disease; 2003 p. 470-84.
Rustin GJS, Newlands ES, Lutz JM, Holden L, Bagshawe KD, Hiscox JG, et al. Combination but not single agent chemotherapy for gestational trophoblastic tumours (GTT) increases the incidence of seconds tumours. J Clin Oncol 1996;14:2769-73.
Lorigan PC, Sharma S, Bright N, Coleman RE, Hancock BW. Characteristics of women with recurrent molar pregnancies. Gynecol Oncol 2000; 78:288-92.
Pregnancy After Assisted Reproductive Technology Edited by Eric R. M. Jauniaux, Botros R. M. B. Rizk, Cambridge University Press 2012.
Savage PM, Sita-Lumsden A, Dickson S, Iyer R, Everard J, Coleman R, et al. The relationship of maternal age to molar pregnancy incidence, risks for chemotherapy and subsequent pregnancy outcome. J Obstet Gynaecol. 2013 May;33(4):406-11.
Abdalla EM, Hayward BE, Shamseddin A, Nawar MM. Recurrent hydatidiform mole: detection of two novel mutations in the NLRP7 gene in two Egyptian families. Eur J Obstet Gynecol Reprod Biol 2012;164:211-5.
